The FDA has approved adalimumab-adbm (Cyltezo, Boehringer Ingelheim), a biosimilar of Humira (AbbVie) for multiple indications.
Adalimumab-adbm, which is administered by subcutaneous injection, is the second FDA approval related to Humira. The first, adalimumab-atto (Amjevita, Amgen), was approved almost a year ago.